AI Engines For more Details: Perplexity Kagi Labs You
Burn Wounds: Mafenide hydrochloride is used to prevent and treat infections in burn wounds. Burn injuries create an open wound that is vulnerable to bacterial colonization and infection. Mafenide hydrochloride works by penetrating the burned tissue and inhibiting the growth of a wide range of bacteria, including gram-positive and gram-negative organisms.
Antibacterial Action: Mafenide hydrochloride exerts its antibacterial action by interfering with the synthesis of folic acid within bacterial cells, which is essential for bacterial growth and replication. By inhibiting folic acid synthesis, mafenide hydrochloride effectively kills bacteria and prevents their proliferation within the burn wound.
Broad Spectrum: Mafenide hydrochloride has a broad spectrum of activity against many types of bacteria commonly found in burn wounds, including Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter species, Staphylococcus aureus, and Streptococcus pyogenes.
Penetrating Action: Mafenide hydrochloride has the ability to penetrate eschar, the dead tissue that forms over the burn wound, allowing it to reach the underlying viable tissue where bacteria may proliferate. This penetration enhances its effectiveness in preventing and treating infections.
Reduction of Sepsis Risk: By preventing and treating infections in burn wounds, mafenide hydrochloride helps reduce the risk of systemic infection (sepsis) and other complications associated with severe burns. Prompt and effective treatment with mafenide hydrochloride is essential for optimizing wound healing and preventing further tissue damage.
Pain Management: Mafenide hydrochloride may cause a stinging or burning sensation upon application, which can be managed with appropriate wound care and pain management techniques. Despite this discomfort, the benefits of preventing and treating infections outweigh the temporary discomfort associated with its use.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.6 | |
| ADHD | 3.6 | 0.6 | 5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.2 | 2.2 | |
| Allergies | 4.7 | 2.6 | 0.81 |
| Allergy to milk products | 1.4 | 0.7 | 1 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 5.8 | 6.2 | -0.07 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.4 | 0.3 | 7 |
| Ankylosing spondylitis | 3.1 | 1.8 | 0.72 |
| Anorexia Nervosa | 1.1 | 2.9 | -1.64 |
| Antiphospholipid syndrome (APS) | 1.2 | 0.3 | 3 |
| Asthma | 4.1 | 1.1 | 2.73 |
| Atherosclerosis | 1.8 | 2.5 | -0.39 |
| Atrial fibrillation | 3.5 | 2.2 | 0.59 |
| Autism | 9.3 | 7.8 | 0.19 |
| Autoimmune Disease | 0.7 | -0.7 | |
| Barrett esophagus cancer | 0.6 | 0.6 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.5 | 1.5 | |
| Bipolar Disorder | 1.8 | 1.7 | 0.06 |
| Brain Trauma | 0.3 | 1.1 | -2.67 |
| Breast Cancer | 0.9 | 0.3 | 2 |
| Cancer (General) | 0.9 | 1.7 | -0.89 |
| Carcinoma | 3.8 | 2.3 | 0.65 |
| Celiac Disease | 2.7 | 2.9 | -0.07 |
| Cerebral Palsy | 0.8 | 1.3 | -0.63 |
| Chronic Fatigue Syndrome | 5.4 | 6.9 | -0.28 |
| Chronic Kidney Disease | 3.6 | 2.3 | 0.57 |
| Chronic Lyme | 0.3 | 0.8 | -1.67 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 1.7 | -0.89 |
| Chronic Urticaria (Hives) | 0.5 | 1.2 | -1.4 |
| Coagulation / Micro clot triggering bacteria | 0.4 | 1 | -1.5 |
| Cognitive Function | 3 | 1 | 2 |
| Colorectal Cancer | 5.4 | 1.9 | 1.84 |
| Constipation | 1.5 | 0.8 | 0.88 |
| Coronary artery disease | 1.5 | 3 | -1 |
| COVID-19 | 7.5 | 11.4 | -0.52 |
| Crohn's Disease | 8.1 | 5.5 | 0.47 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1 | -1 | |
| deep vein thrombosis | 2.5 | 1.1 | 1.27 |
| Denture Wearers Oral Shifts | 1.2 | 1.2 | |
| Depression | 9.2 | 7.6 | 0.21 |
| Eczema | 1.4 | 0.8 | 0.75 |
| Endometriosis | 1.7 | 2 | -0.18 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.2 | 1.5 | 0.47 |
| erectile dysfunction | 1.4 | 1.4 | |
| Fibromyalgia | 2.8 | 2.3 | 0.22 |
| Functional constipation / chronic idiopathic constipation | 4.5 | 4 | 0.13 |
| gallstone disease (gsd) | 3.1 | 0.8 | 2.88 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 0.9 | 1.67 |
| Generalized anxiety disorder | 1.9 | 1.3 | 0.46 |
| giant cell arteritis | 0.2 | -0.2 | |
| Gout | 1.8 | 0.8 | 1.25 |
| Graves' disease | 1.6 | 2.7 | -0.69 |
| Gulf War Syndrome | 0.6 | 1.2 | -1 |
| Halitosis | 1.5 | 1.5 | |
| Hashimoto's thyroiditis | 3 | 0.9 | 2.33 |
| Heart Failure | 3.6 | 1.6 | 1.25 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.3 | 0.3 | 3.33 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 0.6 | 0.9 | -0.5 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 2.9 | 4.5 | -0.55 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 2.1 | 0.6 | 2.5 |
| IgA nephropathy (IgAN) | 1.6 | 5.2 | -2.25 |
| Inflammatory Bowel Disease | 7.7 | 7.8 | -0.01 |
| Insomnia | 1.6 | 2.1 | -0.31 |
| Intelligence | 1.4 | 0.6 | 1.33 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 6.1 | 4.7 | 0.3 |
| ischemic stroke | 1.4 | 1.1 | 0.27 |
| Liver Cirrhosis | 6.3 | 3.1 | 1.03 |
| Long COVID | 6.5 | 6.8 | -0.05 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 1 | -0.11 |
| Mast Cell Issues / mastitis | 0.6 | 0.6 | 0 |
| ME/CFS with IBS | 0.8 | 2.1 | -1.63 |
| ME/CFS without IBS | 1.7 | 2.1 | -0.24 |
| Menopause | 0.6 | 0.5 | 0.2 |
| Metabolic Syndrome | 6.4 | 6.3 | 0.02 |
| Mood Disorders | 9.2 | 6.1 | 0.51 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.1 | 2 |
| Multiple Sclerosis | 4.4 | 6.4 | -0.45 |
| Multiple system atrophy (MSA) | 0.6 | 0.4 | 0.5 |
| myasthenia gravis | 0.7 | -0.7 | |
| neuropathic pain | 0.3 | 2.8 | -8.33 |
| Neuropathy (all types) | 0.4 | 1.7 | -3.25 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.4 | 3.3 | 0.33 |
| NonCeliac Gluten Sensitivity | 1 | 0.3 | 2.33 |
| Obesity | 8.5 | 6.5 | 0.31 |
| obsessive-compulsive disorder | 5.1 | 3.1 | 0.65 |
| Osteoarthritis | 1.8 | 0.6 | 2 |
| Osteoporosis | 1.9 | 1 | 0.9 |
| pancreatic cancer | 0.9 | 0.9 | |
| Parkinson's Disease | 5.1 | 6.5 | -0.27 |
| Polycystic ovary syndrome | 6.7 | 2.6 | 1.58 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | 0 |
| primary biliary cholangitis | 0.9 | 1.4 | -0.56 |
| Primary sclerosing cholangitis | 2.1 | 3.2 | -0.52 |
| Psoriasis | 2.3 | 3.4 | -0.48 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.9 | 4.4 | 0.57 |
| Rosacea | 0.3 | 0.7 | -1.33 |
| Schizophrenia | 5.5 | 2.8 | 0.96 |
| scoliosis | 0.3 | 1.2 | -3 |
| Sjögren syndrome | 2.3 | 2.3 | 0 |
| Sleep Apnea | 1.9 | 1.8 | 0.06 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.9 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 1.4 | |
| Stress / posttraumatic stress disorder | 2.3 | 2.4 | -0.04 |
| Systemic Lupus Erythematosus | 4 | 2.2 | 0.82 |
| Tic Disorder | 1.2 | 1.5 | -0.25 |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 3.6 | 2.2 | 0.64 |
| Type 2 Diabetes | 7.7 | 5.9 | 0.31 |
| Ulcerative colitis | 5.2 | 7.1 | -0.37 |
| Unhealthy Ageing | 5.6 | 2.2 | 1.55 |
| Vitiligo | 1.9 | 1.2 | 0.58 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
